0000899243-22-009826.txt : 20220307 0000899243-22-009826.hdr.sgml : 20220307 20220307204527 ACCESSION NUMBER: 0000899243-22-009826 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220303 FILED AS OF DATE: 20220307 DATE AS OF CHANGE: 20220307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marshall Robert J. Jr. CENTRAL INDEX KEY: 0001754976 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 22720110 MAIL ADDRESS: STREET 1: C/O LANTHEUS MEDICAL IMAGING, INC. STREET 2: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-03 0 0001521036 Lantheus Holdings, Inc. LNTH 0001754976 Marshall Robert J. Jr. C/O LANTHEUS HOLDINGS, INC. 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 0 1 0 0 CFO and Treasurer Common Stock 2022-03-03 4 A 0 25911 0.00 A 152843 D Common Stock 2022-03-04 4 S 0 2570 49.983 D 150273 D Stock Option (right to buy) 49.93 2022-03-03 4 A 0 14773 0.00 A 2032-03-03 Common Stock 14773 14773 D Consists of 8,637 restricted stock units that vest in equal installments over a three-year period and 17,274 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. The option vests in three equal annual installments beginning on March 3, 2023. /s/ Daniel M. Niedzwiecki, attorney-in-fact 2022-03-07